Fireside Chat – Bill Burkoth – Pfizer Ventures

ByWhite Hat

Published: 2018-10-18 13:08:37


Bill Burkoth is currently an Executive Director of Pfizer Ventures, the venture capital arm of Pfizer Inc. Since joining Pfizer in early 2004, Bill has played an instrumental role in numerous new venture capital investments, including Avid Radiopharmaceuticals (acquired by Eli Lilly), Clovis Oncology (Nasdaq: CLVS), DVS Sciences (acquired by Fluidigm), Evolution Benefits (acquired by Genstar Capital), HandyLab (acquired by Becton Dickinson), and HD Biosciences (acquired by Wuxi AppTec).  Bill currently serves on the board of directors of AMRA, Biodesy, DIR Technologies, G-Con Manufacturing, NeuMoDx Molecular, Novocure (Nasdaq: NVCR), Palleon Pharma, RefleXion Medical, and Strata Oncology.  He is also a member of the investment committee of the Investment Fund for Health in Africa (IFHA) and FinHealth Gestão de Recursos S.A. (Rio, Brazil).  Prior to joining Pfizer, Bill worked in Business Development at Galileo Pharmaceuticals and at IntraBiotics Pharmaceuticals. Prior to his roles in business development, Bill was an analyst at Bay City Capital. Mr. Burkoth received a BA in chemistry from Whitman College and an MBA from Columbia Business School.

Categories: Thought Leaders
Sign in or Create an account to comment!